Consequently, it is essential to prioritize shared decision-making and individualized risk-benefit assessments for prescribing GLP-1 RAs, while avoiding misuse with off-label indications
described a 75-year-old man who developed bilateral CBH and fourth ventricular hemorrhage after undergoing lumbar laminectomy for a lumbar stenosis from L1 to L5 [12]
However, these observations do not constitute evidence that tirzepatide treats Hashimoto's disease itself
However, the accelerated approval pathway means that evidence is still interim: while part one of the ESSENCE trial demonstrated improvement in liver scarring and inflammation, it does not yet show whether semaglutide reduces the risk of serious outcomes such as cirrhosis, liver failure or liver cancer
The withdrawal pattern typically involves gradual return of appetite over 2 to 4 weeks, followed by weight regain over the subsequent months
With that promise comes a practical question: What about side effects